BrightInsight Launches Digital Disease Management Solution for Biopharma and Medtech at BIO 2022
June 13, 2022 09:00 ET
|
BrightInsight
BIO 2022 Booth #2637, SAN DIEGO and SAN JOSE, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- – BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital...
Societal to Participate in Upcoming Investor Conferences
May 19, 2022 07:00 ET
|
Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 19, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
May 18, 2022 08:17 ET
|
InvestorBrandNetwork (IBN)
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
BrightInsight Adds Biopharma Technology and Digital Health Expert, Karl Hick, to Advisory Council
May 17, 2022 08:00 ET
|
BrightInsight
SAN JOSE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the...
Societal CDMO Unveils “20/80 Second Source Technical Transfer” Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing
May 17, 2022 07:00 ET
|
Societal CDMO, Inc.
Preparedness Strategy Provides BioPharmas an Opportunity to Mitigate Supply Chain Risks and Vulnerabilities While Initially Committing a Fraction of the Total Tech Transfer Investment Proactive...
Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments
May 12, 2022 08:00 ET
|
Monopar Therapeutics Inc.
Validive® Phase 2b/3 VOICE Trial Continues Enrolling Patients Toward InterimCamsirubicin Phase 1b Dose-Escalation Trial Clears 3rd Dose Level, Now Enrolling 4th WILMETTE, Ill., May 12, 2022 (GLOBE...
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
May 02, 2022 07:30 ET
|
Nevakar, Inc.
BRIDGEWATER, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile...
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
April 28, 2022 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
March 22, 2022 16:01 ET
|
Longboard Pharmaceuticals, Inc.
SAN DIEGO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines...
Mycotopia Therapies Inc. To Enter $13 Billion Medicinal Mushroom Market With HAVN Life Sciences' Biopharmaceuticals And Ei.Ventures MANA Products
March 21, 2022 08:30 ET
|
Mycotopia Therapies Inc.
MIAMI, March 21, 2022 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the “Company”), a biopharma company focused on research, technology, and the development of medical psychedelics,...